BCM
PTCT icon

Bridgeway Capital Management’s PTC Therapeutics PTCT Stock Holding History

Bridgeway Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Hold
22,000
– – 0.03% 602
2026
Q1 		$1.5M Sell
22,000
-6,100
-22% -$432K 0.03% 608
2025
Q4 		$2.13M Sell
28,100
-13,700
-33% -$996K 0.04% 514
2025
Q3 		$2.57M Buy
+41,800
New +$2.18M 0.05% 471
2016
Q2 		– Sell
-85,800
Closed -$553K – 1471
2016
Q1 		$553K Buy
+85,800
New +$1.49M 0.01% 1000

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bridgeway Capital Management's PTCT Position: Q2 2026 in Review

Bridgeway Capital Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 22,000 shares worth $1.79M. The position accounts for 0.03% of the portfolio, ranked #602.

Bridgeway Capital Management first reported a position in PTCT in Q1 2016 and has held it in 5 quarters since. The position peaked at $2.57M in Q3 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Bridgeway Capital Management held 22,000 shares of PTC Therapeutics worth $1.79M as of Q2 2026.
  • Bridgeway Capital Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.03% of Bridgeway Capital Management's portfolio in Q2 2026, its #602 holding.
  • Bridgeway Capital Management first reported a position in PTC Therapeutics in Q1 2016 and has held it in 5 quarters since.
  • Bridgeway Capital Management's PTC Therapeutics position peaked at $2.57M in Q3 2025.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.